TNFSF11 and metabolic disease: Diagnostic accuracy studies are also warranted to show whether OPG and RANKL may serve as predictors of metabolic diseases or their severity, as well as clinical trials to show the efficacy of anti-RANKL treatment in metabolic diseases beyond the bone.